Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Picropodophyllin (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Ependymoma; Glioblastoma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 12 Sep 2013 Planned end date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 18 Jul 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.